Damora Announces Redomestication from Delaware to Cayman Islands

Rhea-AI Summary

Damora (NASDAQ: DMRA) completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026. Each Delaware common share converted into one Cayman ordinary share, and each preferred share converted into the corresponding Cayman series. Nasdaq trading will continue under “DMRA” with a new CUSIP, G2646Y104, effective July 20, 2026. According to Damora, the move does not change its business, management, obligations, assets, or liabilities.

Market reaction after redomestication to Cayman Islands: DMRA +4.10% in the Jul 17 session

+4.10%

3 alerts

+4.10% Session close to close

$1.91B Market Cap

0.2x Rel. Volume

In the Jul 17 session, DMRA gained 4.10%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Context from the platform shows low short positioning and recent insider net selling of 245 shares t...

Analysis

Context from the platform shows low short positioning and recent insider net selling of 245 shares tied to tax obligations. Against that backdrop, this redomestication appears as a structural, non-operational change; investors may watch future filings for any tax, governance, or capital-structure implications.

Key Figures

Ordinary share par value: $0.00001 per share Redomestication effective date: July 16, 2026 New CUSIP effective date: July 20, 2026

3 metrics

Ordinary share par value $0.00001 per share Par value of Damora ordinary shares after redomestication

Redomestication effective date July 16, 2026 Date redomestication from Delaware to Cayman Islands became effective

New CUSIP effective date July 20, 2026 Date ordinary shares begin trading under CUSIP G2646Y104 on Nasdaq

Historical Context

5 past events · Latest: Jul 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 01	Inducement grants	Neutral	+10.7%	Equity inducement options for nine new hires under Nasdaq Rule 5635(c)(4).
Jun 01	Inducement grants	Neutral	-0.1%	Inducement stock options for six new non-executive employees.
May 12	1Q26 earnings report	Positive	+4.6%	Strong cash balance and pipeline progress with timelines for first filings.
May 01	Inducement grants	Neutral	-1.2%	Option awards to two new hires with standard 10-year term and vesting.
Mar 30	Leadership comp grants	Neutral	-4.8%	Equity inducement grants including options and RSUs to new CEO and hires.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The stock often shows modest reactions to routine governance and compensation news, with occasional sharp moves on otherwise neutral announcements.

Key Terms

redomestication, par value, preferred stock, cusip

4 terms

redomestication regulatory

"announced the completion of the redomestication of the Company from the State of Delaware to the Cayman Islands"

Redomestication is a company changing its legal home from one country or state to another by re-registering or swapping shares, much like a person moving their official address to a new jurisdiction. Investors care because that legal home determines tax rules, shareholder rights, regulatory oversight and listing requirements, which can affect dividend treatment, voting power, legal protections and the ease of buying or selling the stock.

par value financial

"one ordinary share, par value $0.00001 per share, of the Company"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

preferred stock financial

"each outstanding share of any series of the Delaware Company’s preferred stock automatically converted"

Preferred stock is a type of ownership in a company that typically offers investors higher and more consistent dividend payments than common stock. Unlike regular shares, preferred stock usually doesn’t come with voting rights but provides a priority claim on the company’s assets and profits, making it a more stable and predictable investment option. This makes preferred stock attractive to those seeking steady income with lower risk.

cusip financial

"will trade on Nasdaq under a new CUSIP – G2646Y104"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the completion of the redomestication of the Company from the State of Delaware to the Cayman Islands, effective on July 16, 2026. Each outstanding share of the Delaware Company’s common stock automatically converted into one ordinary share, par value $0.00001 per share, of the Company, and each outstanding share of any series of the Delaware Company’s preferred stock automatically converted into one outstanding share of the corresponding series of the preferred shares of the Company. The redomestication was previously approved by the Company’s board of directors and subsequently approved by the stockholders of the Company at a Special Meeting of Stockholders held on February 9, 2026.

Effective on July 20, 2026, the Company’s ordinary shares will trade on Nasdaq under a new CUSIP – G2646Y104. The Company’s ordinary shares will continue to be traded on Nasdaq under the symbol “DMRA”. The redomestication will not result in any change to the Company’s business, management, obligations, assets or liabilities.

About Damora Therapeutics
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.

Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to the Company’s expectations, hopes, beliefs, intentions or strategies regarding the Company’s assets, pipeline and business and the expected timing of the effectiveness on Nasdaq of a new CUSIP for the Company’s ordinary shares. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the Company will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those uncertainties and factors described under the headings “Risk Factors,” “Cautionary Information Regarding Forward-Looking Statements” or “Cautionary Statement Regarding Forward-Looking Statements” in the Company’s most recent filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.

Media Contact:

Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com 

Investor Contact:

Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com 

FAQ

What did Damora (NASDAQ: DMRA) announce about its redomestication on July 17, 2026?

Damora announced it completed redomestication from Delaware to the Cayman Islands effective July 16, 2026. According to Damora, this corporate change keeps its business, management, obligations, assets, and liabilities unchanged while updating its place of incorporation and share structure details.

How are Damora (DMRA) shares affected by the redomestication to the Cayman Islands?

Each Delaware common share automatically converted into one Cayman ordinary share, with the same one-for-one treatment for preferred shares. According to Damora, this conversion preserves existing ownership proportions while aligning all equity into newly issued Cayman ordinary and preferred share classes.

Will Damora (DMRA) keep trading on Nasdaq after redomesticating to the Cayman Islands?

Damora’s ordinary shares will continue trading on Nasdaq under the symbol DMRA. According to Damora, only the CUSIP will change to G2646Y104 effective July 20, 2026, while the listing venue and ticker symbol remain the same for investors.

Did Damora shareholders approve the redomestication to the Cayman Islands (DMRA)?

Yes. The redomestication was first approved by Damora’s board and later by shareholders at a Special Meeting on February 9, 2026. According to Damora, these approvals authorized moving the company’s legal domicile from Delaware to the Cayman Islands.

Does Damora’s redomestication (DMRA) change its business or management?

According to Damora, the redomestication will not change its business, management, obligations, assets, or liabilities. The shift is described as a legal and jurisdictional change, leaving operating activities and leadership structure as they were before the move.